Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation

Mark S. Walker, Edward J. Stepanski, Arthur C. Houts, Carolina Reyes, Sacha Satram Hoang, Lee Schwartzberg

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear. Methods: We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3–5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy. Results: Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients. Conclusions: Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.

Original languageEnglish (US)
Pages (from-to)129-139
Number of pages11
JournalTherapeutic Advances in Hematology
Volume2
Issue number3
DOIs
StatePublished - Jan 1 2011

Fingerprint

Follicular Lymphoma
Quality of Life
Observation
Maintenance
Therapeutics
Induction Chemotherapy
Linear Models
Patient Care
Rituximab
Psychology

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation. / Walker, Mark S.; Stepanski, Edward J.; Houts, Arthur C.; Reyes, Carolina; Satram Hoang, Sacha; Schwartzberg, Lee.

In: Therapeutic Advances in Hematology, Vol. 2, No. 3, 01.01.2011, p. 129-139.

Research output: Contribution to journalArticle

Walker, Mark S. ; Stepanski, Edward J. ; Houts, Arthur C. ; Reyes, Carolina ; Satram Hoang, Sacha ; Schwartzberg, Lee. / Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation. In: Therapeutic Advances in Hematology. 2011 ; Vol. 2, No. 3. pp. 129-139.
@article{0e56da60c5914fccb38837e93a3f014c,
title = "Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation",
abstract = "Background: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear. Methods: We reviewed the charts of 137 patients (53{\%} female, 87{\%} White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65{\%} with advanced disease; 48{\%} with a high FLIPI score [3–5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy. Results: Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients. Conclusions: Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.",
author = "Walker, {Mark S.} and Stepanski, {Edward J.} and Houts, {Arthur C.} and Carolina Reyes and {Satram Hoang}, Sacha and Lee Schwartzberg",
year = "2011",
month = "1",
day = "1",
doi = "10.1177/2040620711407675",
language = "English (US)",
volume = "2",
pages = "129--139",
journal = "Therapeutic Advances in Hematology",
issn = "2040-6207",
publisher = "Sage Publications",
number = "3",

}

TY - JOUR

T1 - Symptom burden and quality of life in patients with follicular lymphoma undergoing maintenance treatment with rituximab compared with observation

AU - Walker, Mark S.

AU - Stepanski, Edward J.

AU - Houts, Arthur C.

AU - Reyes, Carolina

AU - Satram Hoang, Sacha

AU - Schwartzberg, Lee

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear. Methods: We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3–5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy. Results: Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients. Conclusions: Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.

AB - Background: The impact on health related quality of life (HRQoL) of rituximab maintenance (R-M) versus observation (OBS) after induction for treatment of follicular lymphoma (FL) is unclear. Methods: We reviewed the charts of 137 patients (53% female, 87% White, age 61.0 ± 12.4 years) who received either R-M (n = 53) or OBS (n = 84) after chemotherapy induction for newly diagnosed FL at community oncology practices within the US. Patients (65% with advanced disease; 48% with a high FLIPI score [3–5]) had completed ≥1 Patient Care Monitor HRQoL survey in the period following front-line therapy, and were excluded if they had progressed during front-line therapy. Results: Linear mixed models showed that postinduction, most symptoms were stable, with patients on R-M reporting HRQoL that was equal to that reported by OBS patients. Conclusions: Among R-M patients, receipt of rituximab was associated with improved psychological symptoms.

UR - http://www.scopus.com/inward/record.url?scp=84993767789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993767789&partnerID=8YFLogxK

U2 - 10.1177/2040620711407675

DO - 10.1177/2040620711407675

M3 - Article

VL - 2

SP - 129

EP - 139

JO - Therapeutic Advances in Hematology

JF - Therapeutic Advances in Hematology

SN - 2040-6207

IS - 3

ER -